DanCann Pharma A/S announced that 1,224,993 outstanding warrants, which were exercisable between 29 December 2025 and 12 January 2026 due to the company's delisting application from the Spotlight Stock Market, have not been exercised. As a result, these warrants have lapsed. DanCann Pharma A/S, a Danish biopharmaceutical company founded in 2018 and focused on cannabinoids, is listed on the Spotlight Stock Market. The company also issued a caution regarding forward-looking statements, noting that actual results may differ from expectations due to various risks and uncertainties.

On January 7, 2026, the board of DanCann Pharma A/S applied for a voluntary delisting of its shares from the Spotlight Stock Market. This application has now been approved, and the shares will be delisted on January 22, 2026. After delisting, the shares will be traded over-the-counter (OTC) and will no longer be subject to certain regulatory obligations. Shareholders are advised to consult their platforms for guidance on their accounts, as the delisting may affect their tax positions. DanCann Pharma A/S, founded in 2018, is a Danish biopharmaceutical company focused on cannabinoids.

On 6 October 2025, DanCann Pharma A/S announced its decision to apply for a voluntary delisting of its shares from the Spotlight Stock Market, contingent on approval by the general meeting. This approval was granted on 21 October 2025. The formal application for delisting was submitted on 7 January 2026. A separate press release will be issued once Spotlight Stock Market decides on the application. For more details on the delisting, including the timeline and reasons, reference is made to the press release dated 6 October 2025. DanCann Pharma A/S is a Danish biopharmaceutical company founded in 2018, focusing on cannabinoids, and is listed on the Spotlight Stock Market in Copenhagen/Stockholm. The release also contains forward-looking statements, which involve risks and uncertainties that could cause actual results to differ from those anticipated. The company does not commit to updating these statements unless required by law. For further inquiries, contact Carsten Trads, Chairman, via email at ctr@dancann.com.

DanCann Pharma A/S has provided a New Year update on recent strategic developments, including the sale of CannGros ApS to StenoCare A/S and the upcoming delisting of DanCann Pharma A/S. Post-delistment, the company's assets will include shares in StenoCare, cash, and a GMP-certified production facility, BP1. Some StenoCare shares have been sold to support operations and settle debts with minor creditors. DanCann will continue to provide services to StenoCare until the end of Q1 2026. The company's future strategy depends on selling BP1, with ongoing discussions with potential buyers. The board is focused on protecting shareholder value and evaluating strategic options. Further updates will be provided as necessary. Carsten Trads, Chairman of the Board, provided contact information for more details on the delisting. DanCann Pharma A/S, a cannabinoid-based biopharmaceutical company founded in 2018, is listed on the Spotlight Stock Market. The update includes forward-looking statements with inherent risks and uncertainties, and the company advises caution in relying on these statements.

On October 6, 2025, the board of DanCann Pharma A/S decided to apply for a voluntary delisting of its shares from the Spotlight Stock Market, a move approved by the general meeting on October 21, 2025. The company plans to submit the delisting request on January 7, 2026, with the last trading day set for January 22, 2026, pending approval. This delisting triggers an "Exit" event for the company's 1,224,993 outstanding warrants, allowing them to be exercised from now until January 12, 2026. Each warrant can be converted into one share at DKK 2.60, potentially increasing the company's share capital by DKK 1,224,993. A list of warrant holders and their respective holdings is provided, and they are instructed to exercise their warrants by emailing the company by January 12, 2026. DanCann Pharma A/S, founded in 2018, is a Danish biopharmaceutical company focused on cannabinoids and is currently listed on the Spotlight Stock Market. The company also includes a forward-looking statement cautioning about potential risks and uncertainties that could affect future outcomes.

DanCann Pharma and StenoCare have finalized an agreement where StenoCare acquires all shares of CannGros, a subsidiary of DanCann Pharma. The acquisition is a share-for-share exchange, with StenoCare issuing 5,000,000 new shares to DanCann Pharma. This transaction makes StenoCare the leading provider of prescription-based medical cannabis in Denmark, expanding its product range from four to nine products and potentially increasing annual revenues by DKK 4–6 million. CannGros, known for its flos and granular cannabis products, complements StenoCare's oil-based products, creating operational synergies. The acquisition allows StenoCare to utilize its existing infrastructure without additional investments. DanCann Pharma, now a major shareholder in StenoCare, aims to benefit from StenoCare's future growth and market consolidation. The integration of CannGros into StenoCare is underway, expected to complete by mid-2026, with no anticipated disruptions.

DanCann Pharma reported net sales of DKK 1.6 million in Q3 2025, a 37% increase from Q2 2025 but a 13% decrease from Q3 2024. The EBITDA improved to -DKK 1.0 million in Q3 2025, showing a 53% improvement from the previous quarter. Operating profit also improved, indicating progress in performance. Founder and CEO Jeppe Krog Rasmussen stepped down, with Chairman Carsten Trads as Interim CEO, and plans to appoint Peter Hauberg Søndergaard as the new CEO. The company will delist from the Spotlight Stock Market following shareholder approval, with plans for OTC trading to maintain transparency. DanCann Pharma remains focused on profitability and long-term value creation despite market volatility.

An extraordinary general meeting of DanCann Pharma A/S was held on October 21, 2025, in Denmark. The main agenda was to approve a proposal by the board of directors to apply for a voluntary delisting of the company's shares from the Spotlight Stock Market and to amend the company's articles of association accordingly. Attorney-at-law Michael Kristensen chaired the meeting, confirming that it was properly convened with 75,000 votes represented. The proposal required a 2/3 majority vote, which was achieved as it was unanimously adopted. The board plans to apply for delisting on January 7, 2026, with the last expected trading day on January 22, 2026. After delisting, the company's shares will be traded over-the-counter. The meeting concluded with the proposal's adoption.

DanCann Pharma is undergoing significant organizational changes and strategic realignment. The founder and CEO, Jeppe Krog Rasmussen, has resigned to pursue new challenges. Peter Hauberg Søndergaard, previously the CFO, is set to become the new CEO, focusing on guiding the company through a delisting process, improving operational efficiency, and executing a long-term growth plan called Maturity2028. The company plans to voluntarily delist from the Spotlight Stock Market due to high costs, administrative burdens, strategic realignment, reduced capital needs, and limited investor interest and liquidity. The delisting aims to allow DanCann Pharma to allocate resources more efficiently and secure capital through private channels. The Board believes these changes, including the leadership transition and delisting, are in the company's and shareholders' best interest, aiming for future profitability and sustainable growth.

DanCann Pharma A/S has scheduled an extraordinary general meeting for 21 October 2025 to discuss a proposal for voluntarily delisting the company's shares from the Spotlight Stock Market. The board of directors recommends this action due to high costs, administrative burdens, strategic realignment, and limited investor interest. Approval requires a two-thirds majority vote. If approved, the delisting application will be submitted on 7 January 2026, with the last trading day expected on 22 January 2026. Shareholders can attend the meeting in person, by proxy, or vote by post. The meeting will be conducted in English, and relevant documents are available on the company’s website.

DanCann Pharma A/S, a Danish biopharmaceutical company founded in 2018, plans to delist its shares from the Spotlight Stock Market. The decision follows a strategic shift since 2023, focusing on sourcing, import, and distribution, with reduced capital needs and a leaner organization. The board cites high costs and administrative burdens of remaining listed, limited investor interest, and better alignment with private equity markets as reasons for delisting. The proposal requires approval at an extraordinary general meeting and, if accepted, the application for delisting will be submitted on January 7, 2026, with the last trading day expected on January 22, 2026. Post-delisting, shares will trade over-the-counter, and the company will no longer adhere to certain public disclosure obligations but will continue operations and pursue strategic partnerships through private equity.

The financial summary for DanCann Pharma A/S for Q2-2025 shows a decrease in net sales and an increase in losses compared to the same period in 2024. The company experienced continued competitive pressure on its products Bedrocan® and Bediol®. Two new products, Bedrolite® and Bedrobinol®, were added to the portfolio, with their first contributions expected in Q3. The divestment of the production facility Biotech Pharm1 (BP1) is in its final stage. The Chairman of the Board, Carsten Trads, noted ongoing challenges but expressed optimism about future growth, particularly with the new product launches and strategic initiatives. The company's equity ratio remained stable at 0.66 compared to 0.32 in the previous year. DanCann Pharma A/S is a Danish biopharmaceutical company focused on cannabinoids, listed on the Spotlight Stock Market. The report includes forward-looking statements subject to risks and uncertainties.